EMERGENT BIOSOLUTIONS INC. Restricted Cash and Cash Equivalents
EMERGENT BIOSOLUTIONS INC. (EBS) had Restricted Cash and Cash Equivalents of $200.00 thousand as of 2019-09-30, per its 10-Q filed 2019-11-07.
Discontinued › Balance Sheet › Assets
us-gaap:RestrictedCashAndCashEquivalents · last filed 2019-11-07
- 2019-09-30: Restricted Cash and Cash Equivalents $200.00K.
- 2019-06-30: Restricted Cash and Cash Equivalents $200.00K.
- 2019-03-31: Restricted Cash and Cash Equivalents $200.00K.
- 2018-12-31: Restricted Cash and Cash Equivalents $200.00K.
| Period end | Restricted Cash and Cash Equivalents |
|---|---|
| 2019-09-30 | $200.00K 10-Q · filed 2019-11-07 |
| 2019-06-30 | $200.00K 10-Q · filed 2019-08-02 |
| 2019-03-31 | $200.00K 10-Q · filed 2019-05-08 |
| 2018-12-31 | $200.00K 10-Q · filed 2019-11-07 |
| 2012-12-31 | $220.00K 10-K · filed 2013-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |